TransCode Therapeutics Hires Adviser for Strategic Process
TransCode Therapeutics retained Tungsten Advisors to lead a strategic process intended to maximize value of TTX-MC138 and its oncology portfolio.
Related stories
Blackstone Mortgage Trust Reports $327 Million Third-Quarter Net Loss
Blackstone Mortgage Trust reported third-quarter 2026 revenue of $141.9 million, up 7% year over year, and a net loss attributable to the company of $327 million, or $1.95 per dilu
M impact | EQUITY | Oct 29, 2026, 10:57 AM UTC
Willis Towers Watson Q3 Adjusted Earnings and Revenue Rise
Willis Towers Watson reported higher adjusted earnings and revenue in Q3.
M impact | EQUITY | Oct 29, 2026, 10:52 AM UTC
Life Time Q3 Net Income Rises to $106.5 Million; Revenue Climbs 14%
Life Time reported Q3 2026 net income of $106.5 million, up year over year, and revenue of $893.5 million, up 14%.
M impact | EQUITY | Oct 29, 2026, 10:52 AM UTC
West Pharmaceutical Q3 Adjusted Earnings and Sales Rise, Raises 2026 Outlook
M impact | EQUITY | Oct 29, 2026, 10:51 AM UTC
Centrus Energy Begins Centrifuge Shipments for Ohio Expansion
Centrus Energy has begun shipping centrifuges for its Ohio uranium enrichment expansion.
M impact | EQUITY | Oct 29, 2026, 10:51 AM UTC
Yili Q3 Net Profit Falls 5.6% Year Over Year
M impact | EQUITY | Oct 29, 2026, 10:51 AM UTC